Brevan Howard Capital Management’s Immix Biopharma IMMX Stock Holding History

Brevan Howard Capital Management’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$524K	Buy	+57,508	New	+$422K	﹤0.01%	1282

Other funds holding IMMX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Brevan Howard Capital Management's IMMX Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Immix Biopharma (IMMX) in Q1 2026: 57,508 shares worth $524K. The stake represents ﹤0.01% of the portfolio and ranks #1282 among its holdings.

77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

Brevan Howard Capital Management held 57,508 shares of Immix Biopharma worth $524K as of Q1 2026.
Immix Biopharma was a new Brevan Howard Capital Management position in Q1 2026.
Immix Biopharma made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1282 holding.
77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.